Pacira Pharmaceuticals (PCRX)
NASDAQ:PCRX
Want to see PCRX full AI Analyst Report?
Top Page
Pacira Pharmaceuticals
(NASDAQ:PCRX)
Select Model
Select Model
Rating:67Neutral
Price Target:
$27.00
▲(9.22% Upside)
Action:ReiteratedDate:03/03/26
The score is driven primarily by solid underlying financial quality—especially the sharply improved leverage profile and strong, consistent cash generation—tempered by earnings volatility. Technicals are a notable drag given the stock trading below major moving averages, and valuation is also a headwind due to the very high P/E. The latest earnings call is supportive with upbeat guidance and operational/market-access progress, but elevated spending and near-term margin pressures cap upside.
Positive Factors
Improved balance sheet
A materially lower leverage profile (debt-to-equity ~0.01) reduces refinancing and liquidity risk, giving management durable financial flexibility to fund R&D, manufacturing scale-up, or opportunistic M&A without compromising operations over the next several quarters.
Negative Factors
Profitability volatility
swings between loss and low single-digit net margins indicate earnings are not yet reliably scalable. Persistent margin volatility reduces the predictability of cash available for R&D and commercialization and heightens execution risk over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Improved balance sheet
A materially lower leverage profile (debt-to-equity ~0.01) reduces refinancing and liquidity risk, giving management durable financial flexibility to fund R&D, manufacturing scale-up, or opportunistic M&A without compromising operations over the next several quarters.
Read all positive factors
Pacira Pharmaceuticals (PCRX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$948.68M
Dividend YieldN/A
Average Volume (3M)624.57K
Price to Earnings (P/E)164.0
Beta (1Y)0.83
Revenue Growth3.14%
EPS GrowthN/A
CountryUS
Employees788
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.57
Shares Outstanding40,489,895
10 Day Avg. Volume386,911
30 Day Avg. Volume624,573
Financial Highlights & Ratios
PEG Ratio-1.53
Price to Book (P/B)1.66
Price to Sales (P/S)1.59
P/FCF Ratio8.44
Enterprise Value/Market Cap1.43
Enterprise Value/Revenue1.87
Enterprise Value/Gross Profit2.42
Enterprise Value/Ebitda11.16
Forecast
1Y Price Target
$27.50Price Target Upside11.25% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)2.64
Revenue Forecast (FY)$760.85M
Pacira Pharmaceuticals Business Overview & Revenue Model
Company Description
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA...
How the Company Makes Money
Pacira primarily makes money by selling its marketed products to healthcare providers and institutions through U.S.-focused commercialization. The company’s largest revenue stream has historically been product sales of EXPAREL, which is purchased ...
Pacira Pharmaceuticals Earnings Call Summary
Earnings Call Date:Feb 26, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 06, 2026
Earnings Call Sentiment Positive
The call conveys a broadly positive outlook: Pacira reported record gross margins, reinvigorated EXPAREL volume growth (~7% in Q4), expanded payer coverage (102M lives outside the bundle), strengthened IP (21 patents) and secured strategic partnerships (LG Chem, J&J). The company is investing in a promising pipeline (PCRX-201, PCRX-2002) and returned capital via buybacks while maintaining a healthy cash position ($238M). Offsetting items include rising R&D and SG&A (notably +56% R&D and +30% SG&A in Q4), revenue headwinds from buy-mix/discounting tied to a GPO, flat ZILRETTA sales, and near-term margin/inventory pressures. Overall, the positives (top-line momentum, margin expansion, IP runway, partnerships, and pipeline progress) outweigh the near-term cost and execution risks.Positive Updates
Record Revenue and Improved Margins
Fiscal 2025 total revenue of $726,000,000 and fourth-quarter consolidated non-GAAP gross margin improved to 80% (vs. 79% a year ago). Company reported highest gross margins in its history and is targeting a five-percentage-point margin improvement vs. 2024 (76% non-GAAP) by 2030.
Negative Updates
Rising Operating Expenses — R&D and SG&A
Fourth-quarter non-GAAP R&D increased to $34.4M from $22.0M (+~56%), driven by a $5.0M upfront in-license payment and advancing clinical programs. Q4 non-GAAP SG&A rose to $91.9M from $70.6M (+~30%), impacted by business development due diligence and litigation costs.
Read all updates
Q4-2025 Updates
Positive
Negative
Record Revenue and Improved Margins
Fiscal 2025 total revenue of $726,000,000 and fourth-quarter consolidated non-GAAP gross margin improved to 80% (vs. 79% a year ago). Company reported highest gross margins in its history and is targeting a five-percentage-point margin improvement vs. 2024 (76% non-GAAP) by 2030.
Read all positive updates
Company Guidance
Pacira guided 2026 to total revenue of $745–$770M, including EXPAREL sales of $600–$620M (plus ~$7M from an EXPAREL veterinary license), with ZILRETTA and ioverao assumed roughly flat to 2025; non‑GAAP gross margin of 77–79% (Q1–Q3 aided by lower‑cost inventory, Q4 expected below the range), non‑GAAP R&D $105–$115M, non‑GAAP SG&A $320–$340M, stock‑based comp $54–$62M and depreciation of ~$30M for adjusted EBITDA modelers. Management noted 2025 results of $726M revenue, Q4 EXPAREL sales of $155.8M (volumes ≈+7%), Q4 ZILRETTA $33M and ioverao $7M, consolidated Q4 non‑GAAP gross margin of 80% (vs 79% prior year), year‑end cash/investments of $238M, repurchases of $150M in stock (including $50M in Q4) retiring ~2M shares to ~41M outstanding with $150M remaining authorization as of 12/31, 102M lives covered outside the surgical bundle (≈110M early 2026), and operational cadence expectations (Q1 ~1 percentage point lower contribution to EXPAREL sales due to storms, Q2–Q3 balanced, Q4 the largest).Pacira Pharmaceuticals Financial Statement Overview
Summary
Income Statement
64
Positive
Balance Sheet
86
Very Positive
Cash Flow
78
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 726.41M | 700.97M | 674.98M | 666.82M | 541.53M |
| Gross Profit | 519.37M | 530.54M | 490.31M | 467.53M | 401.28M |
| EBITDA | 119.13M | 29.12M | 154.59M | 140.38M | 113.95M |
| Net Income | 7.03M | -99.56M | 41.95M | 15.91M | 41.98M |
Balance Sheet | |||||
| Total Assets | 1.26B | 1.55B | 1.57B | 1.68B | 2.08B |
| Cash, Cash Equivalents and Short-Term Investments | 238.42M | 484.62M | 278.58M | 288.65M | 656.41M |
| Total Debt | 454.38M | 638.85M | 586.04M | 763.39M | 1.13B |
| Total Liabilities | 571.81M | 775.17M | 704.26M | 906.19M | 1.34B |
| Stockholders Equity | 693.11M | 778.35M | 870.13M | 775.01M | 730.41M |
Cash Flow | |||||
| Free Cash Flow | 136.66M | 178.75M | 139.49M | 115.20M | 79.85M |
| Operating Cash Flow | 151.99M | 189.39M | 154.65M | 145.27M | 125.72M |
| Investing Cash Flow | 99.48M | -83.28M | 77.54M | -225.19M | -20.79M |
| Financing Cash Flow | -369.63M | 17.36M | -183.03M | -401.53M | 380.69M |
Pacira Pharmaceuticals Technical Analysis
Positive
24.72
Price Trends
22.69
Positive
23.14
Positive
23.54
Positive
Market Momentum
0.40
Negative
64.00
Neutral
77.97
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PCRX, the sentiment is Positive. The current price of 24.72 is above the 20-day moving average (MA) of 23.22, above the 50-day MA of 22.69, and above the 200-day MA of 23.54, indicating a bullish trend. The MACD of 0.40 indicates Negative momentum. The RSI at 64.00 is Neutral, neither overbought nor oversold. The STOCH value of 77.97 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PCRX.
Pacira Pharmaceuticals Risk Analysis
Pacira Pharmaceuticals disclosed 71 risk factors in its most recent earnings report. Pacira Pharmaceuticals reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Pacira Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | $948.68M | 163.97 | 0.95% | ― | 3.14% | ― | |
67 Neutral | $1.72B | 14.40 | 15.55% | ― | 48.87% | ― | |
61 Neutral | $983.63M | 12.76 | 12.76% | ― | -0.03% | -27.66% | |
57 Neutral | $1.11B | 21.64 | 24.11% | ― | 26.34% | -32.79% | |
55 Neutral | $2.88B | -72.78 | -3.67% | ― | 4.54% | -130.59% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
PCRX
Pacira Pharmaceuticals
24.72
-1.18
-4.56%
SUPN
Supernus Pharmaceuticals
51.39
21.10
69.66%
ANIP
ANI Pharmaceuticals
80.92
12.92
19.00%
AMPH
Amphastar Pharmaceuticals
22.88
-0.62
-2.64%
COLL
Collegium Pharmaceutical
34.41
7.50
27.87%
Pacira Pharmaceuticals Corporate Events
Business Operations and StrategyExecutive/Board Changes
Pacira BioSciences adds seasoned leader to board
Positive
Jan 28, 2026
On January 27, 2026, Pacira BioSciences expanded its Board of Directors from nine to 10 members and appointed veteran biopharmaceutical executive Samit Hirawat, M.D., as a Class III director and member of the Science and Technology Committee, with...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.